Ocrelizumab

(Ocrevus®)

Ocrelizumab

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 300 mg/10 ml)
Drug ClassCD20-directed cytolytic antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • Indicated for the treatment of primary progressive MS in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ocrelizumab (Ocrevus) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is also used to treat primary progressive MS in adults.
  • The information was derived from nine systematic reviews/meta-analyses focusing on various aspects of Ocrelizumab's application in treating MS.
  • In terms of effectiveness, Ocrelizumab has been highlighted as superior in delaying disease progression among Disease Modifying Therapy options for Progressive Multiple Sclerosis. For Relapsing Multiple Sclerosis, it ranks highest against placebo concerning annualized relapse rate and confirmed disability progression at 3 and 6 months.
  • When compared with other therapies such as siponimod and mitoxantrone, or newer agents like ublituximab, analyses consistently demonstrated that Ocrelizumab had superior efficacy in reducing annualized relapse rates and disability progression.
  • Regarding the safety profile, Ocrelizumab showed a comparable level to placebos regarding Serious Adverse Events, positioning it as safer than natalizumab. However, decreasing IgG levels over time were noted, which could potentially correlate with an increased infection risk, requiring further research to fully understand this risk profile.
  • While direct subgroup analyses were sparse, overall evidence suggests broad applicability across both types of MS, with specific strength shown in delaying physical disability progression, but attention needs to be given towards long-term safety, especially concerning immunoglobulin levels and infection risks.

Product Monograph / Prescribing Information

Document TitleYearSource
Ocrevus (Ocrelizumab) Prescribing Information.2024Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines